H. diminuta infection in the permissive rat host does not affect DNBS-induced colitisa
| Treatment . | Weight Change (g) . | MPO (U/mg) . | Clinical Disease Score . | Histology Damage Score . |
|---|---|---|---|---|
| Chronic | ||||
| Control | 1.1 ± 8.8 | 0.6 ± 0.6 | 0.3 ± 0.3 | 2.0 ± 1.0 |
| H. diminuta | 2.0 ± 10.0 | 0.9 ± 0.1 | 0.0 ± 0.0 | 2.8 ± 0.8 |
| DNBS (22 mg ir.) | −19.0 ± 7.9b | 5.6 ± 6.9b | 3.8 ± 0.4b | 6.0 ± 2.7b |
| DNBS + H. diminuta | −10.4 ± 8.2b | 7.6 ± 8.0b | 2.4 ± 0.9b | 4.1 ± 3.3b |
| Acute | ||||
| Control | 2.4 ± 1.3 | 0.4 ± 0.2 | 0.0 ± 0.0 | ND |
| H. diminuta | 2.3 ± 1.1 | 1.2 ± 0.2 | 0.0 ± 0.0 | ND |
| DNBS (22 mg ir.) | −9.8 ± 2.0b | 2.3 ± 0.2b | 2.4 ± 0.2b | ND |
| DNBS + H. diminuta | −6.2 ± 0.2b | 2.2 ± 0.18b | 2.0 ± 0.2b | ND |
| Treatment . | Weight Change (g) . | MPO (U/mg) . | Clinical Disease Score . | Histology Damage Score . |
|---|---|---|---|---|
| Chronic | ||||
| Control | 1.1 ± 8.8 | 0.6 ± 0.6 | 0.3 ± 0.3 | 2.0 ± 1.0 |
| H. diminuta | 2.0 ± 10.0 | 0.9 ± 0.1 | 0.0 ± 0.0 | 2.8 ± 0.8 |
| DNBS (22 mg ir.) | −19.0 ± 7.9b | 5.6 ± 6.9b | 3.8 ± 0.4b | 6.0 ± 2.7b |
| DNBS + H. diminuta | −10.4 ± 8.2b | 7.6 ± 8.0b | 2.4 ± 0.9b | 4.1 ± 3.3b |
| Acute | ||||
| Control | 2.4 ± 1.3 | 0.4 ± 0.2 | 0.0 ± 0.0 | ND |
| H. diminuta | 2.3 ± 1.1 | 1.2 ± 0.2 | 0.0 ± 0.0 | ND |
| DNBS (22 mg ir.) | −9.8 ± 2.0b | 2.3 ± 0.2b | 2.4 ± 0.2b | ND |
| DNBS + H. diminuta | −6.2 ± 0.2b | 2.2 ± 0.18b | 2.0 ± 0.2b | ND |
Values are the mean ± SEM (n = 7 from three experiments in the chronic study and n = 3 in the acute study). Rats received 10 H. diminuta cysticercoids, DNBS was administered 8 days (acute) or 3 mo (chronic) after infection, and rats were assessed 72 h after DNBS treatment.
p < 0.05 compared with controls.